Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2024-06-27 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Section 708A Cleansing Statement 2 pages 210.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Section 708A Cleansing Statement' dated 28 June 2024. It confirms the issuance of 180,000,000 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act 2001. The content focuses on compliance with specific sections of the Corporations Act related to share issuance and disclosure. The document length is 2974 characters, which is relatively short and primarily an announcement of a share issuance event under regulatory requirements. There is no detailed financial data, management discussion, or report attached. This fits the category of a Capital/Financing Update, as it relates to company fundraising and capital structure changes through share issuance.
2024-06-27 English
Change in substantial holding 4 pages 247.6KB
Major Shareholding Notification Classification · 100% confidence The document is an ASX announcement titled 'NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER' and includes a Form 604, which is a statutory form under the Corporations Act 2001 used to notify changes in substantial shareholdings. The content details changes in voting power, relevant interests, and associations of substantial holders. There is no financial performance data, earnings information, or management discussion. The document is regulatory in nature, reporting a change in major shareholding interests. This matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document length is substantial and contains the full form, not just an announcement of a report, so it is not RPA or RNS. Therefore, the correct classification is MRQ with high confidence.
2024-06-06 English
Agreement with Major South Korean Pharma Group Hanlim 3 pages 216.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing a collaboration agreement between Invion Limited and Hanlim Pharma Co., Ltd. for research and development of a treatment for glioblastoma. It focuses on the terms of the collaboration, the background of the companies involved, and the potential market for the treatment. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content is primarily about a partnership agreement and research collaboration, which fits the category of a Capital/Financing Update or a general corporate announcement. However, since it is about a collaboration agreement and not about fundraising or capital structure changes, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-05-07 English
Activities Report and Appendix 4C 8 pages 350.3KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Activity Report and Cash Flow Report for the Quarter Ended 31 March 2024'. It includes detailed financial data such as cash flow statements, operating expenses, cash reserves, and payments to related parties. The presence of an Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (the quarter ended 31 March 2024). It is not merely an announcement of a report but includes the actual financial statements and commentary on business activities and cash flows. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-04-29 English
Presentation at East-West Summit in Singapore 29 pages 2.3MB
Regulatory Filings
2024-03-04 English
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC 6 pages 871.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Invion Limited detailing the results of a preclinical study on the effectiveness of their drug INV043 in combination with immune checkpoint inhibitors (ICIs). It includes study highlights, statistical results, significance of findings, and potential commercial and clinical implications. The content is focused on scientific and clinical study results rather than financial data, management changes, or regulatory filings. It is not a full financial report, earnings release, or investor presentation. The document is a detailed announcement of scientific study results intended for investors and the public, typical of a regulatory announcement on a stock exchange. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a proxy, voting result, or capital change announcement. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a general category for regulatory announcements that do not fit other specific financial or corporate categories.
2024-03-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.